Business & Finance
Halozyme swings to net income of USD63m for 2017
21 February 2018 -

Biotechnology company Halozyme Therapeutics Inc (NASDAQ:HALO) stated on Tuesday that its net income was USD63m (USD0.45 per share) for the full-year ended 31 December 2017.

This reflects an improvement when compared with a net loss of USD103m (USD0.81 per share) in 2016.

Revenue of USD316.6m was generated for the full-year ended 31 December 2017, up over revenue of USD146.7m in 2016.

Research and development expenses of USD150.6m were recorded for the full-year ended 31 December 2017, almost flat from R&D of USD150.8m in 2016.

Login
Username:

Password: